AB1210-HPR MENDELIAN RANDOMIZATION ANALYSIS INDICATES SERUM URATE HAS A CONDITIONAL CAUSAL EFFECT ON SERUM CREATININE AND RENAL FUNCTION
Background: Uric acid, the weak organic acid and the end product of purine nucleotide degradation, is excreted predominantly by the proximal tubules [1] . Although large numbers of epidemiological, molecular and animal studies have focused on various pathogenic effects of serum uric acid, inclding chronic kidney disease (CKD), metabolic syndrome, and coronary artery disease [2] , whether the serum uric acid is an independent risk factor or has causal impact on serum creatinine (SCr) and renal function remains unclear. Objectives: We aim to study the effect of serum uric acid on renal function by applying the method of Mendelian randomization. Methods: The study was represented by estimated glomerular filtration rate (eGFR) with potential confounding factors in 3,734 Chinese subjects. Four genetic variants of uric acid transporter genes (rs1481012 [ABCG2], rs16890979
[SLC2A9], rs2231137 [ABCG2] and rs3799352 (SLC17A1]) were selected for this study as they had highest correlation with serum uric acid in Chinese population in our previous study. In this research, serum uric acid was selected as exposure, genetic risk score of uric acid transporters was selected as instrumental variable, and SCr and eGFR were selected as the outcomes. Results: 1) The results of the analysis showed that increased serum uric acid has a causal effect on reducing estimated glomerular filtration rate in both female population and the subjects who were under 65 years old. Because of protective effects on renal function of ovarian hormones such as estrogen, we postulated that estrogen might be the cause leading to the difference between men and women. 2) We also found that increased serum uric acid led to the damage of renal function in the subjects with normal eGFR value. 3) In addition, the serum uric acid was a risk factor to renal function in the subjects with relative high level of fasting glucose or who were smoking currently. Because of metabolic defects in people affected by diabetes, renal glucose reabsorption was increased, thus further sustaining hyperglycemia in patients. Conclusions: Serum urate has causal effects on renal dysfunction in either female or individuals of under 65, or normal eGFR, or high level of fasting glucose, or current smokers. 
AB1211-HPR THE USE OF SUBCUTANEOUS METHOTREXATE IN POLISH PATIENTS WITH RHEUMATOID ARTHRITIS
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Background: Methotrexate (Mtx) should be the drug of the first choice in rheumatoid arthritis (RA) if there are no contraindications to use it. The efficacy of Mtx is measured by remission or low disease activity and depends on the dose taken. Higher doses (25-30 mg/week) are more effective, but intolerance is the main cause of discontinuation of oral treatment. Subcutaneous Mtx is efficient alternative in those cases. Objectives: The aim of this study was to evaluate subcutaneous Mtx use frequency in Polish patients and change oral form for subcutaneous as well. Methods: The disease activity was assessed by Disease Activity Score 28 (DAS 28) during the first visit (V1) and after 3 months therapy (V2) and compliance with therapy as well. Results: There were 194 RA patients diagnosed by the ACR and 1997 and/or ACR/EULAR 2010 criteria. 144 patients were treated by oral Mtx (group A) and 50 patients (group B) by subcutaneous Mtx at the time of study enrolment (V1).37 patients of group A (26%) required changes in therapy during V2, 24 (17%) were switched to subcutaneous Mtx (group A1). 6 patients of group B (12%) required change of treatment during V2, including 2 patients (4%) with subcutaneous Mtx, who were switched to oral Mtx.The main cause of changing therapy from oral to subcutaneous was gastrointestinal intolerance of high dose of Mtx. 69 patients (12%) of group A required additional steroid therapy compared to 18 (36%) of group B. Average DAS 28 decreased by 0.58 in group A1 in oral treatment and during the subcutaneous treatment time decreased by next 0.23. In group A1 during oral treatment 14 (58%) patients used 25 mg/week and 20 patients (83%) used 25 mg/week during subcutaneous treatment time. 
AB1212-HPR DYNAMICS OF ARTICULAR SYNDROME IN RHEUMATOID ARTHRITIS AGAINST CORRECTION OF PROGESTERONE INSUFFICIENCY
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Background: According to the literature, sex hormones manifest themselves as immune modulators that inhibit the ones and stimulate other immune functions. Studies have shown that patients with RA, decrease of estradiol and particularly progesterone in the blood serum is found in the women of reproductive age. According to the literature, progesterone has a close relationship with T-cell immunity. A value of T-cell deficiency plays an important role in the cause of the autoimmune process Objectives: To study of progesterone correction in RA patients.The aim of this study was to evaluate the effectiveness of progesterone deficiency correction in patients with rheumatoid arthritis based on the analysis of articular syndrome Methods: The study involved 40 patients with a documented diagnosis of RA, women of reproductive age. The study group consisted of 30 patients who had correction of progesterone deficiency background in the pathogenetic therapy. The control group consisted of 10 female patients who are on the pathogenetic therapy. We used the following criteria: disease activity and severity of the articular syndrome with determining of the number of tender and swollen joints, indices of DAS and HAQ. Statistical analysis of the results of research used the method of parametrics of Student criterion Results: Among the patients studied disease duration ranged from 3 months to 19 years (mean age 10±7,2 years), 20 patients (50%), from 5 to 10 years -15 (37.5%), and more than 10 years -5 patients (12.5%). X-ray picture of joint damage in the majority of patients corresponded to stage 2-3 -87.5% (35 patients). Less common muscular disorders (7.5%), mainly in patients taking long-term GC, myalgia and muscle malnutrition were detected in 7.5% and 25% of patients, respectively. In addition to the articular syndrome, the most frequent complaints of general weakness (75%), irritability, sleep disorders and attention (50%), anxiety and anxiety (75%), low-grade temperature (10%) Conclusions: Progesterone deficiency correction in RA patients against pathogenic therapy has improved performance of articular syndrome and improves quality of life, such as vitality, general health and social function as well as it contributes to the positive dynamics of mental health References: [1] Background: Rheumatoid arthritis (RA) is a chronic disease that implies high direct and indirect costs for the health system (1, 2) . According to the needs of the health care system, the clinical interests and the national regulatory framework, it was developed a national registry information of RA patients (3) . Objectives: To show how a registry of information that would meet the RA situation was developed and to present the results obtained from the analysis of the Registry on this first year. Methods: A national RA Registry was created after a comprehensive literature review to identify the relevant variables to determine monitoring indicators used by health insurers and health services providers in the attention of patients with RA. Variables were selected and defined by an agreement with clinical experts, thematic and methodological experts and were evaluated by the Ministry of Health in order to review and approve the structure to gather the information. Results: A structure of 89 variables contained was defined. All entities must report annually to the Registry all the patients with a diagnosis of RA, their clinical and demographic characteristics, and the process of care and costs (3). On its first year the Registry provided a baseline of the disease situation of 68.357 patients with RA. Prevalence, incidence, state of disease and drugs including synthetic and biologic DMARDs were analyzed (Table 1) . Most important results were: mean age 57 years; relation women: men 5.2:1; age at onset of disease: 36 years, mean evolution time of disease: 7 years; population with DAS 28 measured 45.6%; mean DAS-28 2.8; percentage of the patient with DMARD therapy 78.9% and bDMARD 16.5%. Conclusions: A national Registry supported by an official policy, with data from the real world provided for healthcare insurers gives an opportunity to obtain a global vision and to identify failures and strengths in the attention process of RA, and to develop indicators to obtain better outcomes. In the future, through continuous efforts towards improving the quality of care provided, these will allow to monitoring and decreasing the burden of RA in the country and may serve as a model to other countries.
